Email this article TARGET THERAPY FOR DISSEMINATED CANCER OF THE CERVIX UTERI
- Authors: Gorbunova V.A.1, Odintsova A.v1, Khokhlova S.V.1
-
Affiliations:
- Department of Chemotherapy, N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
- Issue: No 3-4 (2009)
- Pages: 125-129
- Section: GYNECOLOGY. NEW TECHNOLOGIES
- Published: 10.11.2009
- URL: https://ojrs.abvpress.ru/ojrs/article/view/329
- DOI: https://doi.org/10.17650/1994-4098-2009-0-3-4-125-129
- ID: 329
Cite item
Full Text
Abstract
The paper gives recent data on the use of target agents, such as erlotinib, gefitinib, cetuximab, bevacizumab, and sorafinib in advanced cancer of the cervix uteri (CCI). Approaches using target drugs in combination with chemotherapy are of the greatest interest. A spec- trum of molecular biomarkers (epidermal and vascular growth factors) in CCI and its correlation with prognosis and treatment response are shown. A number of adverse relations caused by target agents are considered.
About the authors
V. A. Gorbunova
Department of Chemotherapy, N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowRussian Federation
A. v Odintsova
Department of Chemotherapy, N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowRussian Federation
S. V. Khokhlova
Department of Chemotherapy, N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Author for correspondence.
Email: sv.khohlova@mail.ru
Russian Federation
References
Supplementary files
